GlassScriptPhysician profile
Brandon D Tanner
NPI 1750667762
$2,082.69
in general payments reported to CMS, 2019-2025
24 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $307 · 2022: $332 · 2023: $184 · 2024: $765 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,443.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,031.83 | 2021-2025 | |
| Novo Nordisk INC | $151.77 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $101.80 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $83.08 | 2022-2024 | Rexulti |
| Insulet Corporation | $64.63 | 2025 | Omnipod |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.78 | 2024 | Caplyta |
| Corcept Therapeutics | $54.35 | 2024-2025 | Korlym |
| Biogen, INC. | $46.73 | 2024 | Zurzuvae |
| Boston Scientific Corporation | $42.88 | 2023 | Wavewriter Alpha Prime 16 |
| Pfizer INC. | $42.52 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $42.51 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $42.06 | 2025 | Cobenfy |
| Lilly USA, LLC | $41.33 | 2022-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.43 | 2021 | |
| Novartis Pharmaceuticals Corporation | $36.98 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $31.93 | 2023-2024 | Spravato |
| Welch Allyn | $28.57 | 2021 | |
| Dexcom, INC. | $26.87 | 2024 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $25.90 | 2025 | Austedo Xr |
| Neurocrine Biosciences, INC. | $23.40 | 2024 | Ingrezza |
| Viatris Specialty LLC | $21.65 | 2025 | Yupelri |
| Lundbeck LLC | $18.95 | 2025 | Rexulti |
| Exact Sciences Corporation | $17.61 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.